目的  制备脂质体HLA-G抗肿瘤靶药物，并对其形态、包封率和抗体效价等进行研究。 方法  采用薄膜分散法制备脂质体HLA-G抗肿瘤靶药物，并用电子显微镜观察其外观形态；利用高效液相色谱测定该脂质体中游离紫杉醇的含量，计算包封率；采用ELISA测定HLA-G抗体效价和HLA-G抗体紫杉醇脂质体活性。 结果    制得的脂质体HLA-G抗肿瘤靶药物的平均粒径为110.9 nm，平均包封率为55%，合成的目的产物的抗体效价达到了未反应抗体效价的50%。结论  制备的脂质体HLA-G抗肿瘤靶药物相对分子质量适中、载药量较大、稳定性较好，但抗体效价较低，具有广泛的临床应用前景。

Objective  To prepare the liposome HLA-G anti-tumor targeting drug and study its morphology, entrapment efficiency and antibody titer.   Methods    Liposome HLA-G anti-tumor targeting drug was prepared by thin-film dispersion method and its morphology was observed by electron microscope. The content of free paclitaxel was determined by high-performance liquid chromatography and the entrapment efficiency of liposome HLA-G anti-tumor targeting drug was calculated. HLA-G antibody titer and activity of liposome
HLA-G anti-tumor targeting drug were determined by ELISA.  Results  The average diameter and entrapment efficiency of liposome HLA-G anti-tumor targeting drug were 110.9 nm and 55 %, respectively. Antibody titer of lipo-some HLA-G anti-tumor targeting drug was 50 % of the level of unreacted HLA-G antibody titer. Conclusion  The liposome HLA-G anti-tumor targeting drug has moderate relative molecular mass, large drug loading, better stability, lower antibody titer,and broad clinical application prospects.